Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
An increasing number of studies deal with medical options for treatment resistant schizophrenia. If no remission can be achieved with clozapine, a combination of antipsychotics can be considered. The combination of clozapine and cariprazine is rarely studied. Cariprazine is a partial agonist on dopamine D2 and D3 receptors and a pharmaceutically rational add-on to clozapine. Stimulating D3 receptors has been linked to improved cognition and mood, with negligible extrapyramidal side effects. We present two patients with long-term treatment resistant schizophrenia receiving cariprazine and clozapine. Whereas psychotic symptoms worsened, the patients developed extrapyramidal side effects with a Pisa syndrome. The syndrome remitted after discontinuation of cariprazine. Possible explanations by pharmacodynamic interactions and drug specific receptor profiles are discussed.
Abstract
An increasing number of studies deal with medical options for treatment resistant schizophrenia. If no remission can be achieved with clozapine, a combination of antipsychotics can be considered. The combination of clozapine and cariprazine is rarely studied. Cariprazine is a partial agonist on dopamine D2 and D3 receptors and a pharmaceutically rational add-on to clozapine. Stimulating D3 receptors has been linked to improved cognition and mood, with negligible extrapyramidal side effects. We present two patients with long-term treatment resistant schizophrenia receiving cariprazine and clozapine. Whereas psychotic symptoms worsened, the patients developed extrapyramidal side effects with a Pisa syndrome. The syndrome remitted after discontinuation of cariprazine. Possible explanations by pharmacodynamic interactions and drug specific receptor profiles are discussed.
참고문헌 (16)
- Nakajima S, "Neuroimaging findings in treatment-resistant schizophrenia : a systematic review : lack of neuroimaging correlates of treatment-resistant schizophrenia", Schizophr Res, 164, pp.164~175 (2015)
- Iasevoli F, "Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones", Prog Neuropsychopharmacol Biol Psychiatry, 65, pp.34~48 (2016)
- Nucifora FC Jr, "Treatment resistant schizophrenia : clinical, biological, and therapeutic perspectives", Neurobiol Dis, 131, pp.104257~ (2019)
- Li P, "Dopamine targeting drugs for the treatment of schizophrenia : past, present and future", Curr Top Med Chem, 16, pp.3385~3403 (2016)
- Domenico De Berardis, "Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases", Clinical Psychopharmacology and Neuroscience, 19(1), pp.174~178 (2021), 대한정신약물학회[DOI]
- Corponi F, "Novel antipsychotics specificity profile : a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone", Eur Neuropsychopharmacol, 29, pp.971~985 (2019)
- cariprazine : an in vivo positron emission tomography study in nonhuman primates, "Synapse", 2013, 258~264
- Fagiolini A, "Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel", Ann Gen Psychiatry, 19, pp.55~ (2020)
- Walder A, "Drug-induced Pisa syndrome under quetiapine", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.1286~1287 (2009)
- Arora M, "Clozapine effective in olanzapine-induced Pisa syndrome", Ann Pharmacother, 40, pp.2273~2275 (2006)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Gründer G, "Cariprazine, an orally active D2", D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression, 2010, pp.11, 823~832
- Thorn CF, "PharmGKB summary : clozapine pathway, pharmacokinetics", Pharmacogenet Genomics, 28, pp.214~222 (2018)
- Nakamura T, "Clinical pharmacology study of cariprazine(MP-214)in patients with schizophrenia(12-week treatment)", Drug Des Devel Ther, 10, pp.327~338 (2016)
- Caccia S, "A new generation of antipsychotics : pharmacology and clinical utility of cariprazine in schizophrenia", Ther Clin Risk Manag, 9, pp.319~328 (2013)
- Chen HK, "Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.707~708 (2010)